AstraZeneca | Investor Event Presentation Deck

Slide schematic 7/7

callout 1/1 chart 2/2 disclaimer 1/1 table 2/2 title 1/1

Components 7

primary line line disclaimer data data headline

Tools 1

callout/primary: In the sub-population of patients with detectable ESR1m at baseline, camizestrant at both doses produces a clinically meaningful improvement in PFS over fulvestrant

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

before-after-framing 90%

The slide contrasts two patient populations (detectable vs not detectable) to highlight the efficacy of the drug in a specific sub-population.

Find anything

The slide uses a split-panel design to compare two patient cohorts (ESR1m detectable vs not detectable).